Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Chhattisgarh Guv throws spanner in Cong govt's farm law counter

In a setback to the ruling Congress&rsquo; plan to bypass the Centre&rsquo;s farm laws, Chhattisgarh Governor Anusuiya Uikey returned the file sent by the party requesting permission to convene a special assembly session. The state government had sent a proposal to hold the session on October 27 and 28 to introduce a farm Bill that would circumvent the three agriculture Bills passed in Parliament, sources said.
Governor Uikey&nbsp;questioned the need for a special session, citing the monsoon session that concluded 58 days ago. Chief Minister Bhupesh Baghel said his government would soon respond to her objections.

Chhattisgarh Guv throws spanner in Cong govt's farm bill counter

Cong govt's&nbsp;bid to counter farm laws thwarted Guv&nbsp;refuses request for holding assembly&nbsp;session Baghel&nbsp;wants to bring in law&nbsp;to block farm laws Governor Uikey&nbsp;questions need for special session

In a setback to the ruling Congress&rsquo; plan to bypass the Centre&rsquo;s farm laws, Chhattisgarh Governor Anusuiya Uikey returned the file sent by the party requesting permission to convene a special assembly session. The state government had sent a proposal to hold the session on October 27 and 28 to introduce a farm Bill that would circumvent the three agriculture Bills passed in Parliament, sources said.
Governor Uikey&nbsp;questioned the need for a special session, citing the monsoon session that concluded 58 days ago. Chief Minister Bhupesh Baghel said his government would soon respond to her objections.

Kohli takes blame for dropped catches, asks team to 'move on'

Post the embarrassing&nbsp;97-run defeat, RCB&nbsp;skipper takes up the responsibility of the thrashing

After an embarrassing&nbsp;97-run defeat against KXIP, RCB&nbsp;skipper Virat&nbsp;Kohli&nbsp;willfully stepped up to admit his fault. Kohli&nbsp;dropped his counterpart KL Rahul&nbsp;twice on 83 and 90 which eventually costed&nbsp;them the game. Taking up the responsibility of the thrashing, the 31-year-old accepted that had they been able to restrict&nbsp;KXIP&nbsp;to 180, the team wouldn't have been under pressure from ball one of the chase. RCB&nbsp;had a good game and a bad game too, and now it is time to move on and learn from the mistakes we made, he added. RCB&nbsp;is set to face defending champions Mumbai&nbsp;Indians on September&nbsp;28.&nbsp;

Plasma therapy doesn't reduce Covid deaths: ICMR

Use of convalescent plasma therapy in coronavirus-infected patients does not help in reducing mortality or progression to severe Covid-19, an ICMR-fudned&nbsp;study has found

Use of convalescent plasma therapy in coronavirus-infected patients does not help in reducing mortality or progression to severe Covid-19, a multi-centric study funded by the Indian Council of Medical Research has found. The study was conducted across 39 public and private hospitals across India between April 22 to July 14. The study trial included 464 moderately ill coronavirus infected hospitalised patients, of whom 235 were given plasma along with best of standard care while 229 received only standard care. The study found that there was no difference in 28-day mortality or progression to severe disease.

New Delhi, PTI: Use of convalescent plasma therapy in coronavirus-infected patients does not help in reducing mortality or progression to severe Covid-19, a multi-centric study funded by the Indian Council of Medical Research (ICMR) has found.
The 'open-label parallel-arm phase II multicentre randomized controlled trial' (PLACID Trial) was conducted across 39 public and private hospitals across India between April 22 to July 14 to investigate the effectiveness of convalescent plasma (CP) for the treatment of Covid-19, it said.
The convalescent plasma (CP) therapy involves taking antibodies from the blood of a person who has recovered from Covid-19 and transfusing those antibodies into an active coronavirus patient to help kickstart the immune system to fight the infection.
A total of 464 participants (moderately ill Covid-19 patients admitted to hospitals) were enrolled for the study, which has not yet been peer-reviewed and has appeared on medRxiv, a preprint server.
The National Task Force for Covid-19, a committee formed by the ICMR to respond to the pandemic, has reviewed and approved this study, it said.
The Clinical Management Protocols for Covid-19 issued by the Union Health Ministry on June 27 allowed use of convalescent plasma (Off label) for treating coronavirus-infected patients in moderate stage of the illness under "investigational therapies"
This authorisation has been paralleled by questionable practices such as calls for donors on social media, and the sale of CP on the black market with exorbitant price tags in India, the study said.
Additionally, although CP is a safe therapeutic modality, plasmapheresis, plasma storage and NAb measurement are all resource-intensive processes, with a limited number of institutes in the country having the capacity to undertake these activities in a quality-assured manner.
"The CP was not associated with reduction in mortality or progression to severe Covid-19," the study said, adding this trial has high generalisability and approximates real-life setting of CP therapy in settings with limited laboratory capacity.
A prior measurement of neutralising antibody titres in donors and participants may further clarify the role of CP in management of Covid-19, it said.
The study trial included 464 moderately ill coronavirus infected hospitalised patients, of whom 235 were given convalescent plasma along with best of standard care while 229 received only standard care, as per the study.
Those in the intervention arm received two doses of 200 ml of CP, transfused 24 hours apart, in addition to the BSC (best standard of care). The two plasma units were collected preferably from different donors depending on the availability and ABO compatibility to increase chances of receiving CP with NAb, it said.
"The PLACID trial results indicate that there was no difference in 28-day mortality or progression to severe disease among moderately ill Covid-19 patients treated with CP along with BSC compared to BSC alone," the study said.

28

Categories